CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase III clinical study of a novel anti-infective solution, Neutrolin in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also had designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world.

CorMedix was founded in 2006 and is headquartered in Bedminster Township, US

CorMedix has an office in Bedminster Township

Bedminster Township, US (HQ)

200 1430 Us 206

CorMedix's revenue was reported to be $39.6 k in Q1, 2017

USD

## Revenue (Q1, 2017) | 39.6 k |

## Gross profit (Q1, 2017) | 133.1 k |

## Gross profit margin (Q1, 2017), % | 337% |

## Net income (Q1, 2017) | (7.6 m) |

## EBIT (Q1, 2017) | (7.6 m) |

## Market capitalization (25-Jul-2017) | 15.8 m |

## Cash (31-Mar-2017) | 6.8 m |

CorMedix's current market capitalization is $15.8 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 2 k | 189.3 k | 210.1 k | 224.1 k |

## Revenue growth, % | 9359% | 11% | 7% | |

## Cost of goods sold | 201.6 k | 445.8 k | 318.7 k | 366.7 k |

## Gross profit | (199.6 k) | (256.5 k) | (108.6 k) | (142.6 k) |

## Gross profit Margin, % | (9975%) | (136%) | (52%) | (64%) |

## Operating expense total | 4.7 m | 8.6 m | 16.5 m | 24.6 m |

## EBIT | (4.9 m) | (8.9 m) | (16.7 m) | (24.8 m) |

## EBIT margin, % | (245647%) | (4703%) | (7926%) | (11049%) |

## Interest expense | 1.3 k | |||

## Interest income | 668 | 2.7 k | 60.4 k | 126.8 k |

## Pre tax profit | (9.1 m) | |||

## Net Income | (55.4 m) | (20.5 m) | (18.2 m) | (24.6 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 39.7 k | 52.4 k | 31.3 k | 120 k | 35.9 k | 41.4 k | 16.5 k | 44.5 k | 39.6 k |

## Cost of goods sold | (54.5 k) | (36.7 k) | (17.3 k) | (101.8 k) | (35.4 k) | (50.2 k) | (187.2 k) | (43.9 k) | (93.6 k) |

## Gross profit | 94.2 k | 89.1 k | 48.6 k | 221.8 k | 71.3 k | 91.7 k | 203.7 k | 88.4 k | 133.1 k |

## Gross profit Margin, % | 237% | 170% | 155% | 185% | 198% | 221% | 1234% | 199% | 337% |

## R&D expense | (171.9 k) | (292.7 k) | (1.2 m) | (1.8 m) | (1.8 m) | (2.1 m) | (2.8 m) | (6.8 m) | (4.9 m) |

## General and administrative expense | (1.7 m) | (1.6 m) | (4.3 m) | (2.4 m) | (2.9 m) | (2.2 m) | (2 m) | (2.3 m) | (2.6 m) |

## Operating expense total | (1.9 m) | (1.9 m) | (5.5 m) | (4.2 m) | (4.7 m) | (4.3 m) | (4.7 m) | (9.2 m) | (7.6 m) |

## EBIT | (1.9 m) | (1.9 m) | (5.5 m) | (4.1 m) | (4.7 m) | (4.3 m) | (4.9 m) | (9.2 m) | (7.6 m) |

## EBIT margin, % | (4757%) | (3554%) | (17582%) | (3446%) | (13110%) | (10286%) | (29751%) | (20602%) | (19260%) |

## Interest expense | (859) | (3.7 k) | (1.6 k) | (992) | (41) | ||||

## Interest income | 987 | 645 | 543 | 8.8 k | 25 k | 31.6 k | 29.4 k | 32.9 k | 23.4 k |

## Net Income | 3.5 m | (5 m) | (5.5 m) | (4.1 m) | (4.7 m) | (4.2 m) | (4.9 m) | (9.1 m) | (7.6 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 2.4 m | 4.3 m | 11.8 m | 8.1 m |

## Inventories | 80 k | 166.7 k | ||

## Current Assets | 2.9 m | 5 m | 37.1 m | 21.8 m |

## PP&E | 36.1 k | 41.5 k | 37.9 k | 69.7 k |

## Total Assets | 3 m | 5.1 m | 37.1 m | 21.9 m |

## Accounts Payable | 939.8 k | 893.4 k | 1.7 m | 1.6 m |

## Current Liabilities | 1.7 m | 1.4 m | 3.1 m | 4.1 m |

## Total Liabilities | 4.1 m | |||

## Additional Paid-in Capital | 51.7 m | 79.7 m | 128.3 m | 136.9 m |

## Retained Earnings | (76.2 m) | (94.4 m) | (119.2 m) | |

## Total Equity | (4 m) | 3.6 m | 34 m | 17.8 m |

## Financial Leverage | -0.7 x | 1.4 x | 1.1 x | 1.2 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 7.7 m | 5.9 m | 8.8 m | 24.1 m | 14.2 m | 13.2 m | 12 m | 9.8 m | 6.8 m |

## Inventories | 278 k | 677.4 k | 461.4 k | 715 k | 699.1 k | 333.9 k | 157.5 k | 118.2 k | 94.9 k |

## Current Assets | 8.2 m | 6.8 m | 9.7 m | 38.7 m | 39.3 m | 33.6 m | 31.2 m | 28.8 m | 14.9 m |

## PP&E | 54.2 k | 46.9 k | 47 k | 44.7 k | 41.1 k | 34.8 k | 31.9 k | 75.8 k | 63.2 k |

## Total Assets | 8.3 m | 6.8 m | 9.8 m | 38.8 m | 39.3 m | 33.6 m | 31.2 m | 28.8 m | 14.9 m |

## Accounts Payable | 848.6 k | 740.3 k | 1.4 m | 1.1 m | 1.4 m | 1.6 m | 1.1 m | 1.8 m | 1.7 m |

## Current Liabilities | 1.2 m | 1.2 m | 2.1 m | 1.9 m | 2.9 m | 3.1 m | 3.1 m | 5 m | 3.9 m |

## Additional Paid-in Capital | 67.3 m | 79.4 m | 89.2 m | 122.6 m | 126.8 m | 129 m | 131.5 m | 136.3 m | 137.7 m |

## Retained Earnings | (74 m) | (81.7 m) | (85.8 m) | (90.5 m) | (98.6 m) | (103.5 m) | (112.6 m) | (126.8 m) | |

## Total Equity | (1.6 m) | 5.6 m | 7.6 m | 36.9 m | 36.4 m | 30.5 m | 28.1 m | 23.8 m | 11 m |

## Financial Leverage | -5.2 x | 1.2 x | 1.3 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.2 x | 1.4 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (9.1 m) | (20.5 m) | (18.2 m) | (24.6 m) |

## Inventories | 80 k | |||

## Accounts Payable | 939.8 k | 893.4 k | 1.7 m | 1.6 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 3.5 m | (5 m) | (5.5 m) | (4.1 m) | (4.7 m) | (4.2 m) | (4.9 m) | (9.1 m) | (7.6 m) |

## Inventories | 278 k | 677.4 k | |||||||

## Accounts Payable | 848.6 k | 740.3 k | 1.4 m | 1.1 m | 1.4 m | 1.6 m | 1.1 m | 1.8 m | 1.7 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 4.4 k |

## Financial Leverage | 1.4 x |